个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yu Yongfeng[1] * ; Guo Qisen[2] ; Zhang Yongchang[3] ; Fang Jian[4] ; Zhong Diansheng[5] ; Liu Baogang[6] ; Pan Pinhua[7] ; Lv Dongqing[8] ; Wu Lin[9] ; Zhao Yanqiu[10] ; Li Juan[11] ; Liu Zhihua[12] ; Liu Chunling[13] ; Su Haichuan[14] ; Fan Yun[15] ; Zhang Tongmei[16] ; Liu Anwen[17] ; Jin Bo[18] ; Wang Ye[19] ; Zhou Jianying[20] ; Zhang Zhihong[21] ; Ran Fengming[22] ; Song Xia[23] ; Shi Michael[24] ; Su Weiguo[24] ; Lu Shun[25] ;
机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [2]Department of Medical Oncology, Shandong Cancer Hospital, Jinan, China. [3]Department of Lung & Gastrointestinal Oncology, Hunan Cancer Hospital, Changsha, China. [4]Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China. [5]Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China. [6]Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China. [7]Department of Respiratory and Critical Care Medicine, Xiangya Hospital of Central South University, Changsha, China. [8]Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, China. [9]Department II of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China. [10]Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China. [11]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China. [12]Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China. [13]Department of Medical Oncology, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. [14]Department of Medical Oncology, The Second Affiliated Hospital of PLA Air Force Medical University, Xi'an, China. [15]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. [16]Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China. [17]Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. [18]Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. [19]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China. [20]Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. [21]Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, China. [22]Department of Medical Oncology, Hubei Cancer Hospital, Wuhan, China. [23]Department of Medical Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China. [24]HUTCHMED, Shanghai, China. [25]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出处：
DOI： 10.1016/S2213-2600(24)00211-X
ISSN：

摘要：
Savolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced or metastatic METex14-mutated NSCLC.This single-arm, multicohort, multicentre, open-label, phase 3b study was done at 48 hospitals in China in adult (≥18 years) patients with locally advanced or metastatic METex14-mutated NSCLC who had not received previous systemic antitumour therapy. Patients with a bodyweight of 50 kg or more and those with a bodyweight of less than 50 kg received savolitinib once daily at 600 mg or 400 mg, respectively, in 21-day cycles. The primary endpoint was objective response rate assessed by independent review committee (IRC) per Response Evaluation Criteria in Solid Tumours, version 1.1. The full analysis set comprised all patients who received at least one dose of study medication, which was used to assess the efficacy endpoints and baseline and safety data. This study is registered with ClinicalTrials.gov (NCT04923945) and is closed to accrual.Between Aug 31, 2021, and Oct 20, 2023, 125 treatment-naive patients were assessed for eligibility, of whom 87 were enrolled and received savolitinib. The median age of patients was 70·0 years (IQR 65·2-75·8) and 51 (59%) of 87 patients were male and 36 (41%) were female. In the full analysis set, the IRC-assessed objective response rate was 62% (95% CI 51-72) and the investigator-assessed objective response rate was 60% (49-70), showing a high concordance rate (84%). Treatment-related adverse events were reported in 85 (98%) of 87 patients, with peripheral oedema (54 [62%]) being the most common. Two of these treatment-related adverse events led to death (cardiac failure n=1, unknown reasons n=1).Savolitinib showed manageable toxicity and promising efficacy in treatment-naive patients with advanced or metastatic METex14-mutated NSCLC.HUTCHMED and AstraZeneca.Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

基金：
This study was funded by HUTCHMED and AstraZeneca.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 危重病医学 1 区 呼吸系统
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 CRITICAL CARE MEDICINE Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Yu Yongfeng,Guo Qisen,Zhang Yongchang,et al.Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study[J].LANCET RESPIRATORY MEDICINE.2024,12(12):958-966.doi:10.1016/S2213-2600(24)00211-X.
APA：
Yu Yongfeng,Guo Qisen,Zhang Yongchang,Fang Jian,Zhong Diansheng...&Lu Shun.(2024).Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.LANCET RESPIRATORY MEDICINE,12,(12)
MLA：
Yu Yongfeng,et al."Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study".LANCET RESPIRATORY MEDICINE 12..12(2024):958-966

资源点击量：54050 今日访问量：1 总访问量：4615 更新日期：2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号